Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up – Still a Buy?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) shares gapped up prior to trading on Wednesday . The stock had previously closed at $21.30, but opened at $22.00. Chugai Pharmaceutical shares last traded at $21.60, with a volume of 9,892 shares.

Chugai Pharmaceutical Trading Up 1.8%

The firm has a fifty day moving average of $23.39 and a two-hundred day moving average of $24.63. The company has a market cap of $72.30 billion, a PE ratio of 27.81 and a beta of 0.65.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its quarterly earnings data on Thursday, July 24th. The company reported $0.20 earnings per share for the quarter. Chugai Pharmaceutical had a return on equity of 20.80% and a net margin of 33.08%.The company had revenue of $2.01 billion during the quarter. Sell-side analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.